Mylan NV did not wait for the Department of Justice to carry out an investigation of its Medicaid charges for EpiPen (epinephrine). Soon after being questioned about Medicaid rebates for the emergency allergy treatment, the company announced it had reached a $465m settlement with the government.
In an Oct. 7 release, Mylan said it had agreed to the terms of a settlement with the DOJ and...







